The cutoff of transient elastography for the evaluation of portal hypertension should be different according to the etiology?

Validation of non‐invasive diagnosis of CSPH in patients with compensated advanced chronic liver disease according to Baveno VII

“…Previous studies showed the relationship between LSM and the risk of decompensation and the development of HCC in patients with compensated cirrhosis 6–8 . However, there has been no study investigating the usefulness of Baveno VII criteria with a large number of patients and aetiology‐specific analysis.…”

Non-invasive tests-based risk stratification: Baveno VII and beyond

“…The sequential application might especially be important to identify ‘at-risk’ patients with CSPH who are otherwise missed by LSM alone. While the ≥25 kPa cut-off is generally endorsed across all etiologies, the optimal cut-off for CSPH might vary across etiologies [ 14 - 16 ], prompting other NIT, such as SSM/VWF/VITRO, that better reflect the dynamic component of portal hypertension [ 17 ].…”

Baveno VII criteria to predict decompensation in compensated advanced chronic liver disease: Still some shades of grey

“…Additionally, the role cofactors, such as obesity and diabetes, play in disease progression and LSMs values is a matter of further investigation. Apart from expanding NITs in different aetiologies [ 13 ], there is a need for further validate NITs other than transient elastography in cACLD. Another point to explore is the validation of the use of deltas of LSM alone or in combination with other NITs, such as Fibrosis-4 index, and which reduction in stiffness, constitutes an improvement with clinical significance.…”